Zimmer Biomet Holdings Asia Pacific — D&A decreased by 0.6% to $15.30M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 0.7%, from $15.20M to $15.30M. Over 4 years (FY 2021 to FY 2025), Asia Pacific — D&A shows relatively stable performance with a -2.1% CAGR.
High levels relative to revenue may indicate a capital-intensive business model or recent significant asset acquisitions.
The non-cash expense allocated to the Asia Pacific segment representing the systematic write-down of tangible assets and...
Standard accounting metric for all asset-heavy manufacturing and healthcare firms.
zbh_segment_asia_pacific_depreciation_and_amortization| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $16.68M | $16.68M | $16.68M | $15.88M | $15.88M | $15.88M | $15.88M | $15.58M | $15.58M | $15.58M | $15.58M | $15.40M | $15.10M | $15.00M | $15.60M | $15.20M | $15.20M | $15.40M | $15.40M | $15.30M |
| QoQ Change | — | +0.0% | +0.0% | -4.8% | +0.0% | +0.0% | +0.0% | -1.9% | +0.0% | +0.0% | +0.0% | -1.1% | -1.9% | -0.7% | +4.0% | -2.6% | +0.0% | +1.3% | +0.0% | -0.6% |
| YoY Change | — | — | — | — | -4.8% | -4.8% | -4.8% | -1.9% | -1.9% | -1.9% | -1.9% | -1.1% | -3.0% | -3.7% | +0.2% | -1.3% | +0.7% | +2.7% | -1.3% | +0.7% |